All News

For patients with extensive-stage small cell lung cancer, Loqtorzi was shown to improve progression-free survival and overall survival.

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk muscle-invasive urothelial cancer after radical resection.

Celebrating Thanksgivings after cancer has made me appreciate all aspects of life even more and to truly cherish times of laughter and memories.

Patients with advanced Hodgkin lymphoma demonstrated significantly improved survival benefits with an Opdivo regimen versus an Adcetris regimen.

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how treatments are given.

Cassidy Lockwood was nominated for the 2024 CURE Extraordinary Healer Award for her exceptional patient-first care, expert knowledge and compassionate support of patients with cancer.

When my daughter was diagnosed with a rare form of brain cancer, I was unsure about clinical trials but eventually learned that it was a lifeline that would save her.

Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.

Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment.

Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for platinum-based chemotherapy.

When I am triggered by something related to the cancer I have, I start going down a negative rabbit hole but remind myself to be vigilant when this happens.

From the deaths of actor Paul Teal and Chicago Bulls player Bob Love to a contestant on “Jeopardy!” revealing his colon cancer diagnosis, here’s what’s happening in the oncology space this week.

Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.

Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses.

With Thanksgiving coming soon, I find that November is the perfect time to reflect and gather feelings of gratitude as a cancer survivor.

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of radiotherapy to TKI treatment.

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

During the holiday season, overwhelming feelings are OK to have, whether you are a patient with cancer or a caregiver.

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.

New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.